Last updated: February 25, 2026
What Is the Drug Associated with NDC 68084-0494?
NDC 68084-0494 is identified as Ketamine Hydrochloride Injection, 100 mg/mL. It is used as an anesthetic and analgesic in clinical settings. The drug’s primary indications include anesthesia induction, procedural sedation, and pain management.
Market Landscape Overview
Regulatory Status and Approvals
- FDA Approval: Ketamine Hydrochloride Injection received FDA approval for anesthesia uses. Recently, off-label use for depression treatment has increased popularity.
- Legal and Regulatory Trends: Several states in the U.S. have approved or are considering legislation for medical use of ketamine for psychiatric indications, influencing demand.
Key Market Participants
- Drug Manufacturers: Major players include PACIFIC NATURAL PRODUCTS and Par Pharmaceutical.
- Distribution Channels: Hospital pharmacies, outpatient clinics, and compounding pharmacies.
- Reimbursement Environment: Reimbursement through Medicare, Medicaid, and private insurers impacts price points and market accessibility.
Market Size and Growth Drivers
- Estimated Market Size (2022): Approximately $150 million for injectable ketamine in the U.S.
- Compound Annual Growth Rate (2023-2028): Projected at 8-10%, driven by increased off-label clinical use and demand for mental health therapies.
- Global Expansion: Countries in Europe and Asia pursue regulatory pathways, potentially tripling market size by 2030.
Competitive Dynamics
- Generic Drugs: The market is dominated by generic formulations with significant price pressure.
- New Formulations: Intranasal and oral formulations targeting psychiatric indications are emerging, potentially substituting injectable forms.
- Pricing Influencers: Manufacturing costs, patent status, formulary inclusion, and clinical demand heavily influence pricing.
Price Analysis and Projections
Current Pricing Benchmarks
| Parameter |
Approximate Price (USD) |
Notes |
| Per Vial (100 mg/mL, 10 mL) |
$15 - $35 |
Wholesale Acquisition Cost (WAC), varies by provider |
| Reimbursed Price per Dose |
$20 - $50 |
Medicaid, Medicare, private insurance reimbursements |
| Cost to Patient |
$50 - $150 |
Out-of-pocket payments, depending on pharmacy markup |
Price Trends (2022-2023)
- Stable wholesale prices due to generic competition.
- Reimbursement rates have increased slightly for psychiatric indications.
- Market-driven price fluctuations driven by supply chain disruptions, especially during COVID-19.
Forecasted Price Movements (2024-2028)
| Year |
Expected Price Range (USD) |
Impacts |
| 2024 |
$20 - $40 |
Slight decrease in wholesale, stabilization in reimbursement |
| 2025 |
$22 - $45 |
Rising demand for psychiatric use impacts premium pricing |
| 2026 |
$23 - $50 |
Entry of alternative formulations limits price escalation |
| 2027 |
$24 - $55 |
Potential premium prices for formulary inclusion for mental health |
| 2028 |
$25 - $60 |
Market saturation, but high demand for off-label use sustains prices |
Key Price Influencers
- Regulatory Changes: Expanded FDA approval or legislative approval for psychiatric indications could increase demand.
- Supply Chain: Disruptions during health emergencies threaten pricing stability.
- Market Penetration: Increased use in mental health treatments may create premium pricing opportunities.
- Formulation Innovations: Alternatives like nasal spray formulations could pressure injectable prices.
Market Risks and Opportunities
Risks
- Regulatory restrictions on off-label use could moderate growth.
- Price competition from compounded formulations and alternative drug delivery systems.
- Supply shortages driven by manufacturing issues or raw material constraints.
Opportunities
- Expansion into psychiatric indications can create new revenue streams.
- Differentiation via formulation improvements that enhance safety and efficacy.
- Emerging markets offer expansion potential due to increasing acceptance and regulation.
Key Takeaways
- NDC 68084-0494, ketamine hydrochloride injection, faces a competitive market with stable wholesale prices influenced by generics.
- Demand driven by anesthesia and emerging psychiatric indications is expected to rise, supporting a price range of $20-$60 by 2028.
- Reimbursement policies and regulatory changes are critical to future pricing trajectory.
- The rise of alternative formulations and regional expansion could challenge or augment the injectable market.
- The overall market CAGR is projected at around 8-10% through 2028.
FAQs
1. What are the primary indications for NDC 68084-0494?
Anesthesia induction, procedural sedation, and off-label psychiatric treatments.
2. How does competition affect the drug’s pricing?
Generic availability maintains price stability and suppresses price hikes.
3. Are there new formulations affecting the market?
Yes. Nasal sprays and oral formulations for psychiatric use are gaining acceptance.
4. What factors could lead to a price increase?
Regulatory approval for psychiatric indications, increased demand, and formulary inclusion.
5. What are the main risks to market growth?
Regulatory restrictions, supply chain disruptions, and price competition from alternative therapies.
References
[1] U.S. Food and Drug Administration. (2022). FDA approval database.
[2] MarketWatch. (2023). Ketamine market data.
[3] IQVIA. (2022). Healthcare Market Trends Report.
[4] Statista. (2023). Global mental health treatment market.
[5] Drug Channels Institute. (2023). Generic drug price trends.
